Peapack Gladstone Financial Corp Has $2.36 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Peapack Gladstone Financial Corp cut its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,248 shares of the biopharmaceutical company’s stock after selling 20 shares during the quarter. Peapack Gladstone Financial Corp’s holdings in Regeneron Pharmaceuticals were worth $2,362,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Rakuten Securities Inc. grew its position in shares of Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 19 shares during the period. Stephens Consulting LLC acquired a new stake in Regeneron Pharmaceuticals in the second quarter worth $26,000. Sachetta LLC increased its stake in Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares in the last quarter. FSA Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at about $26,000. Finally, Family Firm Inc. bought a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $33,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 1.3 %

NASDAQ REGN opened at $731.30 on Friday. The business’s fifty day moving average is $849.77 and its 200-day moving average is $1,004.02. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The stock has a market capitalization of $80.36 billion, a price-to-earnings ratio of 18.10, a PEG ratio of 2.32 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a one year low of $728.68 and a one year high of $1,211.20.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Piper Sandler dropped their price target on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Morgan Stanley cut their target price on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Evercore ISI decreased their price target on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Truist Financial dropped their price objective on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, BMO Capital Markets decreased their target price on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. One analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $1,099.90.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.